Apogee Therapeutics (APGE) Non-cash Items (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Non-cash Items data on file, last reported at $268.2 million in Q1 2026.

• Quarterly Non-cash Items rose 681450.39% year-over-year to $268.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.2 million (up 681450.39% YoY) and the FY2025 annual result came in at $1.9 million, up 166.86% from the prior year.
• Non-cash Items improved to $268.2 million in Q1 2026 per APGE's latest filing, from $216.2 million in the prior quarter.
• Across five years, Non-cash Items topped out at $268.2 million in Q1 2026 and bottomed at $16154.0 in Q4 2023.
• The 4-year median for Non-cash Items is $1.3 million (2023), against an average of $47.0 million.
• The widest annual swing landed in 2024, when Non-cash Items slumped 98.22%; it then surged 681450.39% in 2026.
• Tracing APGE's Non-cash Items over 4 years: stood at $16154.0 in 2023, then surged by 380647.8% to $61.5 million in 2024, then surged by 251.46% to $216.2 million in 2025, then gained by 24.05% to $268.2 million in 2026.
• Per Business Quant, the three latest APGE Non-cash Items figures stand at $268.2 million (Q1 2026), $216.2 million (Q4 2025), and $1.7 million (Q3 2025).

Peer Comparison